OncoCyte Price to Free Cash Flow Ratio 2014-2025 | IMDX
Historical price to free cash flow ratio values for OncoCyte (IMDX) since 2014.
For more information on how our historical price data is adjusted see the Stock Price Adjustment Guide.
| OncoCyte Price to Free Cash Flow Ratio Historical Data |
| Date |
Stock Price |
TTM FCF per Share |
Price to FCF Ratio |
| 2025-06-20 |
3.76 |
|
0.00 |
| 2025-03-31 |
3.06 |
$-1.40 |
0.00 |
| 2024-12-31 |
2.38 |
$-1.62 |
0.00 |
| 2024-09-30 |
2.85 |
$-1.93 |
0.00 |
| 2024-06-30 |
2.95 |
$-1.96 |
0.00 |
| 2024-03-31 |
2.93 |
$-2.11 |
0.00 |
| 2023-12-31 |
2.50 |
$-3.04 |
0.00 |
| 2023-09-30 |
3.12 |
$-4.60 |
0.00 |
| 2023-06-30 |
4.60 |
$-6.05 |
0.00 |
| 2023-03-31 |
7.08 |
$-7.18 |
0.00 |
| 2022-12-31 |
6.42 |
$-9.01 |
0.00 |
| 2022-09-30 |
14.60 |
$-8.52 |
0.00 |
| 2022-06-30 |
18.00 |
$-9.09 |
0.00 |
| 2022-03-31 |
29.80 |
$-9.21 |
0.00 |
| 2021-12-31 |
43.40 |
$-8.59 |
0.00 |
| 2021-09-30 |
71.20 |
$-8.81 |
0.00 |
| 2021-06-30 |
114.80 |
$-8.26 |
0.00 |
| 2021-03-31 |
103.80 |
$-8.66 |
0.00 |
| 2020-12-31 |
47.80 |
$-8.31 |
0.00 |
| 2020-09-30 |
27.80 |
$-8.71 |
0.00 |
| 2020-06-30 |
38.20 |
$-8.72 |
0.00 |
| 2020-03-31 |
49.00 |
$-7.41 |
0.00 |
| 2019-12-31 |
45.00 |
$-8.04 |
0.00 |
| 2019-09-30 |
42.00 |
$-7.14 |
0.00 |
| 2019-06-30 |
49.80 |
$-6.38 |
0.00 |
| 2019-03-31 |
79.00 |
$-7.31 |
0.00 |
| 2018-12-31 |
27.60 |
$-6.17 |
0.00 |
| 2018-09-30 |
50.00 |
$-6.97 |
0.00 |
| 2018-06-30 |
51.00 |
$-7.90 |
0.00 |
| 2018-03-31 |
42.00 |
$-8.38 |
0.00 |
| 2017-12-31 |
93.00 |
$-8.93 |
0.00 |
| 2017-09-30 |
151.00 |
$-8.51 |
0.00 |
| 2017-06-30 |
104.00 |
$-7.12 |
0.00 |
| 2017-03-31 |
119.00 |
$-6.32 |
0.00 |
| 2016-12-31 |
141.00 |
$-5.75 |
0.00 |
| 2016-09-30 |
100.80 |
$-7.63 |
0.00 |
| Sector |
Industry |
Market Cap |
Revenue |
| Medical |
Medical Services |
$0.121B |
$0.002B |
|
OncoCyte Corporation is primarily focused on the development of novel, non-invasive blood and urine diagnostic tests for detection of cancer. OncoCyte Corporation is based in Alameda, California.
|
